Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Jabbour E, Gökbuget N, Advani A, Stelljes M, Stock W, Liedtke M, Martinelli G, O'Brien S, Wang T, Laird AD, Vandendries E, Neuhof A, Nguyen K, Dakappagari N, DeAngelo DJ, Kantarjian H. Jabbour E, et al. Among authors: gokbuget n. Leuk Res. 2020 Jan;88:106283. doi: 10.1016/j.leukres.2019.106283. Epub 2019 Nov 25. Leuk Res. 2020. PMID: 31790983 Free article. Clinical Trial.
[Treatment of adult acute lymphoblastic leukemia].
Gökbuget N, Arnold R, Büchner T, Freund M, Gassmann W, Heil G, Hiddemann W, Löffler H, Lipp T, Ludwig WD, Maschmeyer G, Thiel E, Messerer D, Hoelzer D. Gökbuget N, et al. Praxis (Bern 1994). 1999 Mar 4;88(10):407-20. Praxis (Bern 1994). 1999. PMID: 10199213 Review. German.
Acute lymphoblastic leukemia.
Hoelzer D, Gökbuget N, Ottmann O, Pui CH, Relling MV, Appelbaum FR, van Dongen JJ, Szczepański T. Hoelzer D, et al. Among authors: gokbuget n. Hematology Am Soc Hematol Educ Program. 2002:162-92. doi: 10.1182/asheducation-2002.1.162. Hematology Am Soc Hematol Educ Program. 2002. PMID: 12446423 Review.
Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).
Wassmann B, Pfeifer H, Scheuring U, Klein SA, Gökbuget N, Binckebanck A, Martin H, Gschaidmeier H, Hoelzer D, Ottmann OG. Wassmann B, et al. Among authors: gokbuget n. Leukemia. 2002 Dec;16(12):2358-65. doi: 10.1038/sj.leu.2402770. Leukemia. 2002. PMID: 12454740 Clinical Trial.
207 results